Outcomes of esophagectomy after noncurative endoscopic resection of early esophageal cancer. (December 2019)
- Record Type:
- Journal Article
- Title:
- Outcomes of esophagectomy after noncurative endoscopic resection of early esophageal cancer. (December 2019)
- Main Title:
- Outcomes of esophagectomy after noncurative endoscopic resection of early esophageal cancer
- Authors:
- Dermine, Solène
Leconte, Mahaut
Leblanc, Sarah
Dousset, Bertrand
Terris, Benoit
Berger, Arthur
Berger, Anne
Rahmi, Gabriel
Lepilliez, Vincent
Plomteux, Olivier
Leclercq, Philippe
Coriat, Romain
Chaussade, Stanislas
Prat, Frédéric
Barret, Maximilien - Abstract:
- Background: Current guidelines recommend performing esophagectomy after endoscopic resection for early esophageal cancer when the risk of lymph node metastasis or residual cancer is found to be significant and endoscopic treatment is therefore noncurative. Our aim was to assess the safety and oncological outcomes of esophagogastric resection in this specific clinical setting. Patients and methods: A retrospective review from 2012 to 2018 was performed at four tertiary referral centers. All patients had a noncurative endoscopic resection of a clinical T1 esophageal cancer, followed by esophagectomy. Outcome measures were the rates of T0N0 specimens, overall survival, disease-free and cancer-specific survival, postoperative morbidity and mortality. Results: A total of 30 patients (13 with squamous cell carcinoma and 17 with adenocarcinoma) were included. The reasons for noncurative endoscopic resection were: positive vertical margins ( n = 12), squamous cell carcinoma with muscularis mucosae or submucosal layer invasion ( n = 3 and 9), adenocarcinoma with deep submucosal invasion ( n = 11), poorly differentiated tumor ( n = 6) and lymphovascular invasion ( n = 6). Overall, 63% of the esophagi were T0N0: most residual lesions were T1a metachronous lesions, and four (13%) patients had advanced pT status ( n = 3) or lymph node metastases ( n = 2). Overall survival, disease-free survival and cancer-specific survival were 83%, 75%, and 90% respectively. A total of 43% ofBackground: Current guidelines recommend performing esophagectomy after endoscopic resection for early esophageal cancer when the risk of lymph node metastasis or residual cancer is found to be significant and endoscopic treatment is therefore noncurative. Our aim was to assess the safety and oncological outcomes of esophagogastric resection in this specific clinical setting. Patients and methods: A retrospective review from 2012 to 2018 was performed at four tertiary referral centers. All patients had a noncurative endoscopic resection of a clinical T1 esophageal cancer, followed by esophagectomy. Outcome measures were the rates of T0N0 specimens, overall survival, disease-free and cancer-specific survival, postoperative morbidity and mortality. Results: A total of 30 patients (13 with squamous cell carcinoma and 17 with adenocarcinoma) were included. The reasons for noncurative endoscopic resection were: positive vertical margins ( n = 12), squamous cell carcinoma with muscularis mucosae or submucosal layer invasion ( n = 3 and 9), adenocarcinoma with deep submucosal invasion ( n = 11), poorly differentiated tumor ( n = 6) and lymphovascular invasion ( n = 6). Overall, 63% of the esophagi were T0N0: most residual lesions were T1a metachronous lesions, and four (13%) patients had advanced pT status ( n = 3) or lymph node metastases ( n = 2). Overall survival, disease-free survival and cancer-specific survival were 83%, 75%, and 90% respectively. A total of 43% of patients had severe postoperative complications, and postoperative mortality was 7%. Conclusion: In this cohort, esophagectomy allowed the resection of residual advanced cancer or lymph node metastases in 13% of cases, at the cost of 43% severe morbidity and 7% mortality. Therefore, the possibility of close follow up needs to be balanced with a highly morbid surgical management in these patients. … (more)
- Is Part Of:
- Therapeutic advances in gastroenterology. Volume 12(2019)
- Journal:
- Therapeutic advances in gastroenterology
- Issue:
- Volume 12(2019)
- Issue Display:
- Volume 12, Issue 2019 (2019)
- Year:
- 2019
- Volume:
- 12
- Issue:
- 2019
- Issue Sort Value:
- 2019-0012-2019-0000
- Page Start:
- Page End:
- Publication Date:
- 2019-12
- Subjects:
- endoscopic mucosal resection -- endoscopic submucosal dissection -- esophageal adenocarcinoma -- esophageal squamous cell carcinoma -- esophagectomy -- superficial esophageal cancer
Gastroenterology -- Periodicals
Digestive organs -- Diseases -- Treatment -- Periodicals
Gastrointestinal system -- Diseases -- Treatment -- Periodicals
Liver -- Diseases -- Treatment -- Periodicals
Pharmacology -- Periodicals
Gastroenterology -- Periodicals
Gastrointestinal Diseases -- therapy -- Periodicals
Liver Diseases -- therapy -- Periodicals
Pharmacology -- Periodicals
Gastroentérologie -- Périodiques
Appareil digestif -- Maladies -- Traitement -- Périodiques
Tractus gastro-intestinal -- Maladies -- Traitement -- Périodiques
Hépatologie -- Périodiques
Foie -- Maladies -- Périodiques
Pharmacologie -- Périodiques
616.3005 - Journal URLs:
- http://rave.ohiolink.edu/ejournals/issn/1756283x/ ↗
http://tag.sagepub.com/ ↗
http://www.uk.sagepub.com/home.nav ↗
http://www.tag.sagepub.com/ ↗ - DOI:
- 10.1177/1756284819892556 ↗
- Languages:
- English
- ISSNs:
- 1756-283X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 12115.xml